[1]
March L, Smith EU, Hoy DG, et al. Burden of disability due to musculoskeletal (MSK) disorders. Best Pract Res Clin Rheumatol 2014; 28(3): 353-66.
[2]
Carlesso LC, Segal NA, Curtis JR, et al. Knee pain and structural damage as risk factors for incident widespread pain: Data from the multicenter osteoarthritis study. Arthritis Care Res 2017; 69(6): 826-32.
[3]
Man GS, Mologhianu G. Osteoarthritis pathogenesis - a complex process that involves the entire joint. J Med Life 2014; 7(1): 37-41.
[4]
Galvez I, Torres-Piles SD, Hinchado M, et al. Immune-neuroendocrine dysregulation in patients with osteoarthritis: A revision and a pilot study. Endocr Metab Immune Disord Drug Targets 2017; 17(1): 78-85.
[5]
Sokolove J, Lepus CM. Role of inflammation in the pathogenesis of osteoarthritis: Latest findings and interpretations. Ther Adv Musculoskelet Dis 2013; 5(2): 77-94.
[6]
Orlowsky EW, Kraus VB. The role of innate immunity in osteoarthritis: When our first line of defense goes on the offensive. J Rheumatol 2015; 42(3): 363-71.
[7]
Abenavoli L, Pete V. Role of adipokines and cytokines in non-alcoholic fatty liver disease. Rev Recent Clin Trials 2014; 9(3): 134-40.
[8]
Mabey T, Honsawek S. Cytokines as biochemical markers for knee osteoarthritis. World J Orthop 2015; 6(1): 95-105.
[9]
Muzzarelli RA, Greco F, Busilacchi A, Sollazzo V, Gigante A. Chitosan, hyaluronan and chondroitin sulfate in tissue engineering for cartilage regeneration: A review. Carbohydr Polym 2012; 89(3): 723-39.
[10]
Ishimaru D, Sugiura N, Akiyama H, et al. Alterations in the chondroitin sulfate chain in human osteoarthritic cartilage of the knee. Osteoarthritis Cartilage 2014; 22(2): 250-8.
[11]
Morris CJ. Carrageenan-induced paw edema in the rat and mouse. Methods Mol Biol 2003; 225: 115-21.
[12]
Jacobs BY, Dunnigan K, Pires-Fernandes M, Allen KD. Unique spatiotemporal and dynamic gait compensations in the rat monoiodoacetate injection and medial meniscus transection models of knee osteoarthritis. Osteoarthritis Cartilage 2017; 25(5): 750-8.
[13]
Baragi VM, Becher G, Bendele AM, et al. A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: Evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models. Arthritis Rheum 2009; 60(7): 2008-18.
[14]
Towbin H, Schmitz A, Van Oostrum J, et al. Monoclonal antibody based enzyme-linked and chemiluminescent assays for the human interleukin-1 receptor antagonist. Application to measure hIL-1 receptor antagonist levels in monocyte cultures and synovial fluids. J Immunol Methods 1994; 170(1): 125-35.
[15]
Collett D. Modelling survival data in medical research CRC Press 2015: 3; 520
[16]
Luzina IG, Keegan AD, Heller NM, et al. Regulation of inflammation by interleukin-4: A review of “alternatives”. J Leukoc Biol 2012; 92: 753-64.
[17]
Amanvermez R, Gunay M, Piskin A, Keles G, Tomak L. TNF-α, IL-1β, and oxidative stress during fracture healing. Bratisl Lek Listy 2013; 114(11): 621-4.
[18]
Li ZC, Han N, Li X, et al. Decreased expression of microRNA-130a correlates with TNF-α in the development of osteoarthritis. Int J Clin Exp Pathol 2015; 8(3): 2555-64.
[19]
Moelants EA, Mortier A, Van Damme J, Proost P. Regulation of TNF-α with a focus on rheumatoid arthritis. Immunol Cell Biol 2013; 91(6): 393-401.
[20]
Kosek E, Altawil R, Kadetoff D, et al. Evidence of different mediators of central inflammation in dysfunctional and inflammatory pain--interleukin-8 in fibromyalgia and interleukin-1 β in rheumatoid arthritis. J Neuroimmunol 2015; 280: 49-55.
[21]
Zhao L, Ye J, Wu GT, et al. Gentiopicroside prevents interleukin-1 beta induced inflammation response in rat articular chondrocyte. J Ethnopharmacol 2015; 172: 100-7.
[22]
Pope RM, Shahrara S. Possible roles of IL-12-family cytokines in rheumatoid arthritis. Nat Rev Rheumatol 2013; 9(4): 252-6.
[23]
Croxford AL, Kulig P, Becher B. L-12-and IL-23 in health and disease. Cytokine Growth Factor Rev 2014; 25(4): 415-21.
[24]
Hilgenberg E, Shen P, Dang VD, et al. Interleukin-10-producing B cells and the regulation of immunity. Curr Top Microbiol Immunol 2014; 380: 69-92.
[25]
Harsini S, Ziaee V, Maddah M, et al. Interleukin 10 and transforming growth factor beta 1 gene polymorphisms in juvenile idiopathic arthritis. Bratisl Med J 2016; 117(5): 258-62.
[26]
Trifunović J, Miller L, Debeljak Ž, Horvat V. Pathologic patterns of interleukin 10 expression--a review. Biochem Med (Zagreb) 2015; 25(1): 36-48.
[27]
Van Meegeren MER, Roosendaal G, Jansen NW, et al. IL-4 alone and in combination with IL-10 protects against blood-induced cartilage damage. Osteoarthritis Cartilage 2012; 20(7): 764-72.
[28]
Van Meegeren MER, Roosendaal G, Van Veghel K, et al. A short time window to profit from protection of blood-induced cartilage damage by IL-4 plus IL-10. Rheumatology 2013; 52: 1563-71.
[29]
Venkatesha SH, Dudics S, Acharya B, Moudgil KD. Cytokine-modulating strategies and newer cytokine targets for arthritis therapy. Int J Mol Sci 2014; 16(1): 887-906.
[30]
Martel-Pelletier J, Farran A, Montell E, et al. Discrepancies in composition and biological effects of different formulations of chondroitin sulfate. Molecules 2015; 20(3): 4277-89.
32
5